関: chronic lymphocytic leukemia

PrepTutorEJDIC

frequency modulation 周波数変調

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2019/12/21 14:25:15」(JST)

wiki en

B-lymphocyte antigen CD20 or CD20 is expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity.^[5]

In humans CD20 is encoded by the MS4A1 gene.^[6]^[7]

This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule that plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants that encode the same protein.^[7]

Function

The protein has no known natural ligand^[8] and its function is to enable optimal B-cell immune response, specifically against T-independent antigens.^[9] It is suspected that it acts as a calcium channel in the cell membrane.

Expression

CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells.^[10]^[11] It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells.^[12]

Immunohistochemistry can be used to determine the presence of CD20 on cells in histological tissue sections. Because CD20 remains present on the cells of most B-cell neoplasms, and is absent on otherwise similar appearing T-cell neoplasms, it can be very useful in diagnosing conditions such as B-cell lymphomas and leukaemias. However, the presence or absence of CD20 in such tumours is not relevant to prognosis, with the progression of the disease being much the same in either case. CD20 positive cells are also sometimes found in cases of Hodgkins disease, myeloma, and thymoma.^[13]

Antibody FMC7 (Flinders Medical Centre) appears to recognise a conformational variant of CD20^[14]^[15] also known as the FMC7 antigen.^[16]

Clinical significance

CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.

The anti-CD20 mAB ofatumumab (Genmab) was approved by FDA in October 2009 for chronic lymphocytic leukemia.

The anti-CD20 mAB obinutuzumab (Gazyva) was approved by FDA in November 2013 for chronic lymphocytic leukemia.

Additional anti-CD20 antibody therapeutics under development (phase II or III clinical trials in 2008) include :

Obinutuzumab for systemic lupus erythematosus,
Rituximab for myalgic encephalomyelitis
Ocaratuzumab for follicular lymphoma and rheumatoid arthritis,
Ocrelizumab for multiple sclerosis (rheumatoid arthritis discontinued in 2010),
TRU-015 (by Trubion), (discontinued in 2010^[17])
IMMU-106 (veltuzumab).^[18] for non-Hodgkin's lymphoma or (2015) immune thrombocytopenia.

B cells, CD20, and diabetes mellitus

A link between the immune system's B cells and diabetes mellitus has been determined.^[19] In cases of obesity, the presence of fatty tissues surrounding the body's major organ systems results in cell necrosis and insulin desensitivity along the boundary between them. Eventually, the contents of fat cells that would otherwise have been digested by insulin are shed into the bloodstream. An inflammation response that mobilizes both T and B cells results in the creation of antibodies against these cells, causing them to become less responsive to insulin by an as-yet unknown mechanism and promoting hypertension, hypertriglyceridemia, and arteriosclerosis, hallmarks of the metabolic syndrome. Obese mice administered anti-B cell CD-20 antibodies, however, did not become less responsive to insulin and as a result did not develop diabetes mellitus or the metabolic syndrome, the posited mechanism being that anti-CD20 antibodies rendered the T cell antibodies dysfunctional and therefore powerless to cause insulin desensitivity by a B cell antibody-modulated autoimmune response. The protection afforded by anti-CD-20 lasted approximately forty days—the time it takes the body to replenish its supply of B cells—after which repetition was necessary to restore it. Hence, it has been argued that diabetes mellitus be reclassified as an autoimmune disease rather than a purely metabolic one and focus treatment for it on immune system modulation.^[19]

References

^ ^a ^b ^c GRCh38: Ensembl release 89: ENSG00000156738 - Ensembl, May 2017
^ ^a ^b ^c GRCm38: Ensembl release 89: ENSMUSG00000024673 - Ensembl, May 2017
^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ Hardy, Richard (2008). "Chapter 7: B Lymphocyte Development and Biology". In Paul, William (ed.). Fundamental Immunology (Book) (6th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 237–269. ISBN 978-0-7817-6519-0.
^ Tedder TF, Streuli M, Schlossman SF, Saito H (January 1988). "Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes". Proceedings of the National Academy of Sciences of the United States of America. 85 (1): 208–12. doi:10.1073/pnas.85.1.208. PMC 279513. PMID 2448768.
^ ^a ^b "Entrez Gene: MS4A1 membrane-spanning 4-domains, subfamily A, member 1".
^ Cragg MS, Walshe CA, Ivanov AO, Glennie MJ (2005). The biology of CD20 and its potential as a target for mAb therapy. Current Directions in Autoimmunity. 8. pp. 140–74. doi:10.1159/000082102. ISBN 978-3-8055-7851-6. PMID 15564720.
^ Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E, van Lier RA (January 2010). "CD20 deficiency in humans results in impaired T cell-independent antibody responses" (PDF). The Journal of Clinical Investigation. 120 (1): 214–22. doi:10.1172/JCI40231. PMC 2798692. PMID 20038800.
^ Walport M, Murphy K, Janeway C, Travers PJ (2008). Janeway's Immunobiology (7th ed.). New York: Garland Science. ISBN 978-0-8153-4123-9.
^ Bonilla FA, Bona CA (1996). "5". Textbook of Immunology. Boca Raton: CRC. p. 102. ISBN 978-3-7186-0596-5.
^ Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M (October 2005). "A tumorigenic subpopulation with stem cell properties in melanomas". Cancer Research. 65 (20): 9328–37. doi:10.1158/0008-5472.CAN-05-1343. PMID 16230395.
^ Cooper K, Anthony Leong AS-Y (2003). Manual of diagnostic antibodies for immunohistology (2nd ed.). London: Greenwich Medical Media. ISBN 978-1-84110-100-2.
^ Polyak MJ, Ayer LM, Szczepek AJ, Deans JP (July 2003). "A cholesterol-dependent CD20 epitope detected by the FMC7 antibody". Leukemia. 17 (7): 1384–9. doi:10.1038/sj.leu.2402978. PMID 12835728.
^ Serke S, Schwaner I, Yordanova M, Szczepek A, Huhn D (April 2001). "Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses". Cytometry. 46 (2): 98–104. doi:10.1002/cyto.1071. PMID 11309819.
^ Deans JP, Polyak MJ (February 2008). "FMC7 is an epitope of CD20". Blood. 111 (4): 2492, author reply 2493–4. doi:10.1182/blood-2007-11-126243. PMID 18263793.
^ "Trubion announces Pfizer's decision to discontinue development of TRU-015 for RA". Trubion Pharmaceuticals, Inc. press release. 15 June 2010.
^ Note: information included in this article only found in table present in print version of article. K. John Morrow Jr (15 June 2008). "Methods for Maximizing Antibody Yields". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. p. 36. Retrieved 6 July 2008.
^ ^a ^b Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Paltser G, Tsui H, Wu P, Davidson MG, Alonso MN, Leong HX, Glassford A, Caimol M, Kenkel JA, Tedder TF, McLaughlin T, Miklos DB, Dosch HM, Engleman EG (May 2011). "B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies". Nature Medicine. 17 (5): 610–7. doi:10.1038/nm.2353. PMC 3270885. PMID 21499269. Lay summary – Stanford School of Medicine.

External links

CD20+antigen at the US National Library of Medicine Medical Subject Headings (MeSH)
representations of the shape are found here and more detail here
Human MS4A1 genome location and MS4A1 gene details page in the UCSC Genome Browser.
Human MS4A2 genome location and MS4A2 gene details page in the UCSC Genome Browser.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. マントル細胞リンパ腫の臨床症状、病理学的特徴、および診断clinical manifestations pathologic features and diagnosis of mantle cell lymphoma [show details]
…restriction in up to 80 percent of cases. They also express pan-B cell antigens (eg, CD19, CD20), CD5, and FMC7. Rare cases may be CD5– or CD23+ . A prominent, expanded irregular meshwork of follicular dendritic …
2. ワルデンストレームマクログロブリン血症の疫学、発症機序、臨床症状、診断epidemiology pathogenesis clinical manifestations and diagnosis of waldenstrom macroglobulinemia [show details]
…immunophenotype (eg, surface IgM+, CD5–/+, CD10–, CD11c–, CD19+, CD20+, CD22+, CD23–, CD25+, CD27+, FMC7+, CD103–, CD138–). The plasmacytic component will be CD138+, CD38+ and CD45– or dim. The MYD88 L265P …
3. B細胞前リンパ球性白血病b cell prolymphocytic leukemia [show details]
…IgM +/- IgD, bright surface Ig kappa or lambda light chain, bright CD20, and CD19, CD22, CD79a, and FMC7 This is in contrast to chronic lymphocytic leukemia (CLL) which generally has dim expression of surface …
4. リンパ形質細胞性リンパ腫の臨床症状、病理学的特徴、および診断clinical manifestations pathologic features and diagnosis of lymphoplasmacytic lymphoma [show details]
…typical immunophenotype (eg, surface IgM+, CD5-/+, CD10-, CD19+, CD20+, CD22+, CD23-, CD25+, CD27+, FMC7+, CD103-, CD138-). The plasmacytic component will be CD138+, CD38+ and CD45- or dim. Variations from …
5. T細胞前リンパ球性白血病の臨床症状、病理学的特徴、および診断clinical manifestations pathologic features and diagnosis of t cell prolymphocytic leukemia [show details]
…differ in their immunophenotype. Unlike T-PLL, B-PLL expresses one or more B cell antigens (CD20, CD22, FMC7, CD79a) and lacks T cell antigens. Both T-PLL and mycosis fungoides (MF) are T cell neoplasms that…

English Journal

Is Cd11c and Fmc7 Negativity in Chronic Lymphocytic Leukemia Poor Prognostic?

Şentürk Yikilmaz A, Akinci S, Bakanay ŞM, Zengin ZB, Dilek İ.
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion. 2020 Jan;36(1)84-90.
Chronic lymphocytic leukemia (CLL) is a common hematological malignancy. This study is aimed to investigate the prognostic effect of clinic, laboratory and flow cytometric analysis in CLL patients. Newly diagnosed 55 CLL cases were divided into two groups, as stable disease (Group 1) and progressive
PMID 32158089

An integrated flow cytometry analysis of 286 mature B cell neoplasms identifies CD13 as a useful marker for diagnostic subtyping.

Lau H, Nagy A, Atwater SK, Cascio MJ, Ohgami RS.
International journal of laboratory hematology. 2018 Dec;40(6)715-720.
CD13 is a myeloid associated antigen, which may be expressed by a subset of B cell lymphomas; however, the significance of its expression along with other B cell associated antigens is not well characterized. Two hundred and eighty-six mature B cell neoplasms with flow cytometric analysis performed
PMID 30066366

Low-grade follicular lymphoma involvement of the bone marrow with a mixed paratrabecular, diffuse, and massive pattern expressing typical mantle cell lymphoma immunophenotype CD23-/FMC7+: a case report.

Kim J, Lim JH, Jeong J, Lee SH, Jo JC, Park SH.
Blood research. 2018 Sep;53(3)261-263.
PMID 30310797

Japanese Journal

日本型有毛細胞白血病亜型が疑われ脾摘で診断が確定した脾臓びまん性赤脾髄小細胞型B細胞リンパ腫

山田幸佳,梶原慶三,三浦美代子,田雁万結,押味和夫,白潟智一,菅渉,高橋達郎,清水和義,大島孝一
臨床血液 59(3), 281-286, 2018
… リンパ球表面マーカーはCD19, CD20, CD11c, FMC7, IgM, Igκが陽性で，TRAP染色陰性，IgH鎖JH遺伝子の単クローン性再構成があり，BRAF …
NAID 130006627421

びまん性大細胞型B細胞リンパ腫の組織像を示す皮膚結節を契機に診断されたt(2;18)(p12;q21)を伴う慢性リンパ性白血病/小リンパ球性リンパ腫

小山めぐみ,中島秀明,沼田歩,石山泰史,高崎啓孝,鷲見公太,河内香江,横瀬智之,中村直哉,酒井リカ
臨床血液 58(7), 749-754, 2017
… 末梢血中に核異型を伴う小型リンパ球を4,000/µl認め，flowcytometryではCD5＋, CD10−, CD20＋, CD22＋, CD23dim, FMC7＋, SmIgλ＋, SmIgκ−，末梢血染色体分析でt(2;18)(p12;q21)，＋12を含む異常を認め，FISHではBCL2スプリットシグナル陽性，IGH/CCND1 …
NAID 130005907556

Characteristics of CD5-Positive Splenic Marginal Zone Lymphoma with Leukemic Manifestation ; Clinical, Flow Cytometry, and Histopathological Findings of 11 Cases

KOJIMA Minoru,SATO Eriko,OSHIMI Kazuo,MURASE Takuhei,KOIKE Tadashi,TSUNODA Sinichirou,MATSUMOTO Toshiharu,MARUTSUKA Kousuke,OGIYA Daisuke,MORIUCHI Makiko,TOKUNAKA Mami,YARA KIKUTI Yukie,KIKUCHI Tomoki,NAKAMURA Naoya,ANDO Kiyoshi
Journal of clinical and experimental hematopathology 50(2), 107-112, 2010-11-01
… FMC7, 5/7 ; …
NAID 10027647902

Related Pictures

抗ヒトnon-CD抗体 FMC7（CD20） | サイトメトリードットコム CD200抗体を使用したB-CLLとMCLの解析例アプリケーション 2013. 6.1 歯科指導監査懇談会 | 富山県保険医協会 Successful long-term monotherapy with rituximab in a patient with chronic lymphocytic Mantle Cell Lymphoma (MCL) | Flow Cytometry A rare case of t(11;22) in a mantle cell lymphoma like B-cell neoplasia resulting in a

★リンクテーブル★

「FM」

MS4A1
Available structures
PDB	Ortholog search: PDBe RCSB
List of PDB id codes
	3PP4, 2OSL, 3BKY
Identifiers
Aliases	MS4A1, B1, Bp35, CD20, CVID5, LEU-16, MS4A2, S7, membrane spanning 4-domains A1
External IDs	OMIM: 112210 MGI: 88321 HomoloGene: 7259 GeneCards: MS4A1
Gene location (Human)
Chr.	Chromosome 11 (human)
End	60,470,760 bp
Gene location (Mouse)
Chr.	Chromosome 19 (mouse)
End	11,266,241 bp
RNA expression pattern
	; ;
	More reference expression data
Gene ontology
Molecular function	• epidermal growth factor receptor binding; • protein binding; • MHC class II protein complex binding;
Cellular component	• integral component of membrane; • plasma membrane; • integral component of plasma membrane; • extracellular exosome; • membrane; • external side of plasma membrane; • extracellular; • cell nucleus;
Biological process	• B cell activation; • B cell proliferation; • humoral immune response; • response to bacterium;
	Sources:Amigo / QuickGO
Orthologs
	931
	12482
	ENSG00000156738
	ENSMUSG00000024673
	P11836
	P19437
	NM_152866; NM_021950; NM_152867
	NM_007641
	NP_068769; NP_690605; NP_690606
	NP_031667
	Wikidata
View/Edit Human	View/Edit Mouse

　　[★]

FBM？ fetal breathing movement？

[refGRCh38Ensembl-1] GRCh38: Ensembl release 89: ENSG00000156738 - Ensembl, May 2017

[refGRCm38Ensembl-2] GRCm38: Ensembl release 89: ENSMUSG00000024673 - Ensembl, May 2017

[3] "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[4] "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[Paul0807-5] Hardy, Richard (2008). "Chapter 7: B Lymphocyte Development and Biology". In Paul, William (ed.). Fundamental Immunology (Book) (6th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 237–269. ISBN 978-0-7817-6519-0.

[pmid2448768-6] Tedder TF, Streuli M, Schlossman SF, Saito H (January 1988). "Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes". Proceedings of the National Academy of Sciences of the United States of America. 85 (1): 208–12. doi:10.1073/pnas.85.1.208. PMC 279513. PMID 2448768.

[entrez-7] "Entrez Gene: MS4A1 membrane-spanning 4-domains, subfamily A, member 1".

[pmid15564720-8] Cragg MS, Walshe CA, Ivanov AO, Glennie MJ (2005). The biology of CD20 and its potential as a target for mAb therapy. Current Directions in Autoimmunity. 8. pp. 140–74. doi:10.1159/000082102. ISBN 978-3-8055-7851-6. PMID 15564720.

[pmid20038800-9] Kuijpers TW, Bende RJ, Baars PA, Grummels A, Derks IA, Dolman KM, Beaumont T, Tedder TF, van Noesel CJ, Eldering E, van Lier RA (January 2010). "CD20 deficiency in humans results in impaired T cell-independent antibody responses" (PDF). The Journal of Clinical Investigation. 120 (1): 214–22. doi:10.1172/JCI40231. PMC 2798692. PMID 20038800.

[isbn0-8153-4123-7-10] Walport M, Murphy K, Janeway C, Travers PJ (2008). Janeway's Immunobiology (7th ed.). New York: Garland Science. ISBN 978-0-8153-4123-9.

[Bona-11] Bonilla FA, Bona CA (1996). "5". Textbook of Immunology. Boca Raton: CRC. p. 102. ISBN 978-3-7186-0596-5.

[pmid16230395-12] Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE, Herlyn M (October 2005). "A tumorigenic subpopulation with stem cell properties in melanomas". Cancer Research. 65 (20): 9328–37. doi:10.1158/0008-5472.CAN-05-1343. PMID 16230395.

[Leong-13] Cooper K, Anthony Leong AS-Y (2003). Manual of diagnostic antibodies for immunohistology (2nd ed.). London: Greenwich Medical Media. ISBN 978-1-84110-100-2.

[pmid12835728-14] Polyak MJ, Ayer LM, Szczepek AJ, Deans JP (July 2003). "A cholesterol-dependent CD20 epitope detected by the FMC7 antibody". Leukemia. 17 (7): 1384–9. doi:10.1038/sj.leu.2402978. PMID 12835728.

[pmid11309819-15] Serke S, Schwaner I, Yordanova M, Szczepek A, Huhn D (April 2001). "Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses". Cytometry. 46 (2): 98–104. doi:10.1002/cyto.1071. PMID 11309819.

[pmid18263793-16] Deans JP, Polyak MJ (February 2008). "FMC7 is an epitope of CD20". Blood. 111 (4): 2492, author reply 2493–4. doi:10.1182/blood-2007-11-126243. PMID 18263793.

[17] "Trubion announces Pfizer's decision to discontinue development of TRU-015 for RA". Trubion Pharmaceuticals, Inc. press release. 15 June 2010.

[18] Note: information included in this article only found in table present in print version of article. K. John Morrow Jr (15 June 2008). "Methods for Maximizing Antibody Yields". Genetic Engineering & Biotechnology News. Mary Ann Liebert, Inc. p. 36. Retrieved 6 July 2008.

[Winer_2011-19] Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Paltser G, Tsui H, Wu P, Davidson MG, Alonso MN, Leong HX, Glassford A, Caimol M, Kenkel JA, Tedder TF, McLaughlin T, Miklos DB, Dosch HM, Engleman EG (May 2011). "B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies". Nature Medicine. 17 (5): 610–7. doi:10.1038/nm.2353. PMC 3270885. PMID 21499269. Lay summary – Stanford School of Medicine.

v t e Proteins: clusters of differentiation (see also list of human clusters of differentiation)
1-50	CD1 a-c 1A 1D 1E CD2 CD3 γ δ ε CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33 CD34 CD35 CD36 CD37 CD38 CD39 CD40 CD41 CD42 a b c d CD43 CD44 CD45 CD46 CD47 CD48 CD49 a b c d e f CD50
51-100	CD51 CD52 CD53 CD54 CD55 CD56 CD57 CD58 CD59 CD61 CD62 E L P CD63 CD64 A B C CD66 a b c d e f CD68 CD69 CD70 CD71 CD72 CD73 CD74 CD78 CD79 a b CD80 CD81 CD82 CD83 CD84 CD85 a d e h j k CD86 CD87 CD88 CD89 CD90 CD91 - CD92 CD93 CD94 CD95 CD96 CD97 CD98 CD99 CD100
101-150	CD101 CD102 CD103 CD104 CD105 CD106 CD107 a b CD108 CD109 CD110 CD111 CD112 CD113 CD114 CD115 CD116 CD117 CD118 CD119 CD120 a b CD121 a b CD122 CD123 CD124 CD125 CD126 CD127 CD129 CD130 CD131 CD132 CD133 CD134 CD135 CD136 CD137 CD138 CD140b CD141 CD142 CD143 CD144 CD146 CD147 CD148 CD150
151-200	CD151 CD152 CD153 CD154 CD155 CD156 a b c CD157 CD158 (a d e i k) CD159 a c CD160 CD161 CD162 CD163 CD164 CD166 CD167 a b CD168 CD169 CD170 CD171 CD172 a b g CD174 CD177 CD178 CD179 a b CD180 CD181 CD182 CD183 CD184 CD185 CD186 CD191 CD192 CD193 CD194 CD195 CD196 CD197 CDw198 CDw199 CD200
201-250	CD201 CD202b CD204 CD205 CD206 CD207 CD208 CD209 CDw210 a b CD212 CD213a 1 2 CD217 CD218 (a b) CD220 CD221 CD222 CD223 CD224 CD225 CD226 CD227 CD228 CD229 CD230 CD233 CD234 CD235 a b CD236 CD238 CD239 CD240CE CD240D CD241 CD243 CD244 CD246 CD247 - CD248 CD249
251-300	CD252 CD253 CD254 CD256 CD257 CD258 CD261 CD262 CD263 CD264 CD265 CD266 CD267 CD268 CD269 CD271 CD272 CD273 CD274 CD275 CD276 CD278 CD279 CD280 CD281 CD282 CD283 CD284 CD286 CD288 CD289 CD290 CD292 CDw293 CD294 CD295 CD297 CD298 CD299
301-350	CD300A CD301 CD302 CD303 CD304 CD305 CD306 CD307 CD309 CD312 CD314 CD315 CD316 CD317 CD318 CD320 CD321 CD322 CD324 CD325 CD326 CD328 CD329 CD331 CD332 CD333 CD334 CD335 CD336 CD337 CD338 CD339 CD340 CD344 CD349 CD350

v t e Protein: cell membrane proteins (other than Cell surface receptor, enzymes, and cytoskeleton)
Arrestin	SAG ARRB1 ARRB2 ARR3
Membrane-spanning 4A	MS4A1 MS4A2 MS4A3 MS4A4A MS4A4E MS4A5 MS4A6A MS4A6E MS4A7 MS4A8B MS4A9 MS4A10 MS4A12 MS4A13 MS4A14 MS4A15 MS4A18
Myelin	Myelin basic protein PMP2 Myelin proteolipid protein PLP1 Myelin oligodendrocyte glycoprotein Myelin-associated glycoprotein Myelin protein zero
Pulmonary surfactant	Pulmonary surfactant-associated protein B Pulmonary surfactant-associated protein C
Tetraspanin	TSPAN1 TSPAN2 TSPAN3 TSPAN4 TSPAN5 TSPAN6 TSPAN7 TSPAN8 TSPAN9 TSPAN10 TSPAN11 TSPAN12 TSPAN13 TSPAN14 TSPAN15 TSPAN16 TSPAN17 TSPAN18 TSPAN19 TSPAN20 TSPAN21 TSPAN22 TSPAN23 TSPAN24 TSPAN25 TSPAN26 TSPAN27 TSPAN28 TSPAN29 TSPAN30 TSPAN31 TSPAN32 TSPAN33 TSPAN34
Other/ungrouped	Calnexin LDL-receptor-related protein-associated protein Neurofibromin 2 Presenilin PSEN1 PSEN2 HFE Phospholipid transfer proteins Dysferlin STRC OTOF
see also other cell membrane protein disorders

匿名

検索

案内

案内

FMC7